GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Hainan Haiyao Co 000566.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

4.06

0.00%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Hainan Haiyao Co

Its shares trade on Shenzhen under the ticker 000566.SZ. It has been listed since 25 May 1994. In the fiscal year to 31 December 2025, it reported revenue of CN¥831.2m and a net loss of CN¥430.0m. At that date it held total assets of CN¥5.71bn and shareholders' equity of CN¥81.8m.

Hainan Haiyao Co., Ltd. engages in the research and development, production, and sales of pharmaceuticals and medical devices. The company is headquartered in Haikou, Hainan. The Company’s main products consist of six categories, including cephalosporin series, stomach and intestine medicines, anti-tumor medicines, cochlear implant series, bulk drugs and intermediate series. The firm distributes its products in domestic market and to overseas market, with China as its main market.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
25 May 1994
Employees
2,247

Leadership

Pay as last reported

  • Mr. Jianping WangChairman of the Board, since 2022
  • Ms. Rongyi XuFinance DirectorCN¥204,800
  • Mr. Lei ShiDeputy General Manager, Secretary of the BoardCN¥51,100
  • Ms. Hui ZhangDeputy General ManagerCN¥664,000
  • Mr. Jianpeng WangDirector of Sales
  • Mr. Duojia FengDirector
  • Mr. Chang LiuDirector, since 2020CN¥312,300
  • Mr. Min WenDirector
  • Mr. Yuexiang ZhaoDirectorCN¥354,200
  • Ms. Xiuqun HuIndependent Director
  • Mr. Tao LuIndependent Director
  • Mr. Zhaosheng MengIndependent DirectorCN¥200,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Hainan Haiyao's cephalosporin series is a leading product in the Chinese pharmaceutical market.
  • The company's stomach and intestine medicines have strong domestic market presence.
  • Hainan Haiyao's anti-tumor medicines are well-established in the healthcare sector.

Weaknesses

  • The company's cochlear implant series has limited international market reach.
  • Hainan Haiyao's bulk drugs and intermediate series face competition in China.
  • The firm's overseas market distribution is less developed compared to domestic.

Opportunities

  • Expanding the anti-tumor medicines segment in the growing Chinese healthcare market.
  • Increasing overseas market share for cochlear implant series in emerging economies.
  • Growing demand for stomach and intestine medicines in the domestic market.

Threats

  • Competition from domestic pharmaceutical companies in the cephalosporin series.
  • Regulatory changes affecting bulk drugs and intermediate series in China.
  • Economic slowdown impacting overseas market expansion for medical devices.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.